Intel
INTC
Micron Technology
MU
Oracle
ORCL
NVIDIA
NVDA
Alibaba
BABA
US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 1.170
- 0.0000.00%
Trading Feb 18 10:22 ET
244.12MMarket Cap-1.65P/E (TTM)
1.235High1.170Low1.05MVolume1.190Open1.170Pre Close1.26MTurnover0.52%Turnover RatioLossP/E (Static)208.65MShares3.17952wk High6.22P/B237.18MFloat Cap0.30452wk Low--Dividend TTM202.72MShs Float51.375Historical High--Div YieldTTM5.56%Amplitude0.291Historical Low1.199Avg Price1Lot Size
Sangamo Therapeutics Stock Forum
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$ this quarter result is good or bad? No volume at all
2
Potential Spikes this Month Frfr, SGMO,APGE,UTHR,ZNTL,VTYX,CCCC,OCUL,GHRS,GLUE,RAPP,CING......
2
$Sangamo Therapeutics (SGMO.US)$
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients
$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
3 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR)...
3 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR)...
$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Thursday, 6th February at 8:05 am
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope obs...
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Thursday, 6th February at 8:05 am
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope obs...
1
$Sangamo Therapeutics (SGMO.US)$ sell more, i want good discount
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway | 4D Molecular Therapeutics
2
1
$Sangamo Therapeutics (SGMO.US)$ lets go~~~~up
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
102477371 : When is the results ?
102414580 OP 102477371 : I do search on Google which projected on 18 February